Abstract
Aidi injection (ADI), a traditional Chinese biomedical preparation, is a promising adjuvant therapy for gynecologic tumors (GTs), including cervical cancer (CC), endometrial cancer (EC), and ovarian cancer (OC). Although studies have reported positively on ADI therapy, its exact effects and safety in GT patients remain controversial. Therefore, a wide-ranging systematic search of electronic databases was performed for this meta-analysis. Data from 38 trials including 3309 GT patients were analyzed. The results indicated that the combination of conventional treatment and ADI markedly improved the patients’ overall response rate (P<0.00001), disease control rate (P<0.00001), and quality of life (P<0.05) compared with conventional treatment alone. Furthermore, patient immunity was enhanced with combined treatment, as indicated by significantly increased percentages of CD3+ (P=0.005) and CD4+ (P<0.00001) and increased CD4+/CD8+ ratio (P=0.001). Most of the adverse events caused by radiochemotherapy such as gastrointestinal issues, leukopenia, thrombocytopenia, and hepatotoxicity, (P<0.05 for all) were significantly alleviated when ADI was used in the GT patients. However, other adverse events such as nephrotoxicity, diarrhea, alopecia, and neurotoxicity did not significantly differ between the two groups. Overall, these results suggest that the combination of conventional and ADI treatment is more effective than conventional treatment alone.
Highlights
Gynecologic tumors (GTs) pose a serious threat to the health and well-being of women, as they are the leading causes of cancer-related death worldwide
The results demonstrated that the quality of life (QoL) of GT patients in the combined group was significantly better than that in the control group, indicated by significantly increased quality of life improved rate (QIR) (OR = 3.56, 95% confidence interval (CI) = 2.84–4.45, P
Our analysis demonstrated that the percentages of CD3+ and CD4+ and the CD4+/CD8+ ratios were all significantly increased in GT patients treated with Aidi injection (ADI), indicating that immune function of GT patients improved after ADI adjuvant therapy
Summary
Gynecologic tumors (GTs) pose a serious threat to the health and well-being of women, as they are the leading causes of cancer-related death worldwide. In 2018, approximately 1,247,330 newly diagnosed GT cases and 586,093 GT-related deaths occurred worldwide [1,2]. GT treatment includes different management strategies such as surgery, radiotherapy, and chemotherapy [3–6]. These therapeutic methods have greatly advanced in the past few decades, the prognosis of GT remains poor, as they are mostly diagnosed at stages III or IV [3–10]. In individuals with extensive invasion and distant metastasis, the management of these tumors is typically aimed at enhancing the quality of life (QoL) and survival rate, because current conventional treatments cannot be used to completely remove the tumor [3–6,8–11]. The unpleasant side effects of GT treatment are one of the most important factors limiting the clinical application of radiochemotherapy
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
